Slows the functional decline in patients with amyotrophic lateral sclerosis (ALS).
Pyrazolone free radical scavenger. Although the precise mechanism by which edaravone works in ALS is unknown, it may lessen the effects of oxidative stress, which is thought to be a probable factor in ALS onset and progression.
Initial treatment cycle: Administer 60 mg as an IV infusion over 60 minutes once daily for 14 days, followed by a 14-day drug-free period.
Subsequent treatment cycles: Administer 60 mg as an IV infusion once daily over 60 minutes for 10 of 14 days, followed by a 14-day drug-free period.
Approval was based on a phase 3 trial (MCI186-19), which evaluated 137 people with ALS. Data demonstrated patients who received edaravone for 6 months experienced significantly less decline in physical function (33% reduction or 2.49 ALSFRS-R points; P=0.001).
Tanaka M, et al. A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.189). Presented at the American Academy of Neurology Annual Meeting. Vancouver, BC. 2016 Apr 18.
Medscape © 2018 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L Windle. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review - Medscape - Jan 11, 2018.